-
FGFR2::SHTN1 Fusion and Shootin1 Oncogenicity
2026-09-05
The reference study provides the first molecular characterization of the FGFR2::SHTN1 fusion, showing how Shootin1 coiled-coil domains may convert an intact FGFR2 kinase into a ligand-independent signaling unit. Its combination of fusion mapping, structural modeling, oligomerization analysis, and biochemical validation offers a mechanistic framework for interpreting this alteration in cholangiocarcinoma and related cancers.
-
Tricine-SDS-PAGE Gel Preparation Kit Guide
2026-09-04
The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is designed to improve resolution of low-molecular-weight proteins and peptides that are difficult to distinguish with conventional Tris-glycine SDS-PAGE. It is intended for scientific research workflows, including denaturing electrophoresis and non-denaturing electrophoresis, and is not intended for diagnostic or medical use.
-
AmpliFold Capture-and-Release in Lateral Flow Assays
2026-09-04
The AmpliFold strategy addresses a central sensitivity bottleneck in lateral flow assays by temporarily capturing analyte-bound complexes, triggering their release, and enabling high-affinity rebinding before signal development. In a HER2 model, the reference study reports up to 16-fold improvement in the limit of detection and a 12-fold sensitivity enhancement with large gold nanoparticles, while also identifying linker design, receptor density, and capture geometry as critical variables.
-
Cinoxacin Workflows for Gram-Negative UTI Research
2026-09-03
Cinoxacin provides a historically defined quinolone antibiotic comparator for susceptibility testing, time-kill experiments, and resistance selection in urinary Gram-negative isolates. Its narrow activity profile and practical assay benchmarks make it especially useful for controlled urinary tract infection research rather than broad-spectrum screening.
-
Acridine Orange hydrochloride: Practical Staining Guide
2026-09-03
Acridine Orange hydrochloride provides cell-permeable, differential fluorescence for nucleic acid staining, supporting cell cycle analysis, apoptosis detection, and flow-based DNA/RNA assessment. This guide explains preparation, controls, readout planning, and limitations; it should not be treated as a universal substitute for orthogonal apoptosis or nucleic acid assays.
-
AO/PI Staining Solution for Viability Workflows
2026-09-02
AO/PI Staining Solution delivers a two-color readout for separating nucleated live and membrane-compromised cells, making it useful when trypan blue is vulnerable to debris or red blood cell interference. This article translates that principle into practical workflows for podocyte, PBMC, cytotoxicity, and fluorescence-based cell counting applications.
-
LY294002 Workflows for PI3K Pathway Studies
2026-09-02
LY294002 provides a reversible way to interrogate class I PI3K signaling across pathway, apoptosis, autophagy, and tumor-cell assays. This practical guide connects dose selection and washout experiments with the FGFR–TGFβ–PI3K/AKT regulatory model reported in HER2-positive breast cancer research.
-
Chemotherapy Enhances Neoantigen-Directed T Cell Therapy
2026-09-01
Sagie et al. identify T104, a KRAS.G12V-specific T cell receptor, and show that lymphodepleting chemotherapy can improve neoantigen presentation rather than serving only as preparative treatment. By increasing immunoproteasome activity, HLA-I surface expression, and the abundance of selected presented peptides, chemotherapy enhanced tumor-cell recognition by TCR-T cells, TILs, and T cell engagers across preclinical models.
-
Plerixafor (AMD3100): CXCR4 Research Guide
2026-09-01
Plerixafor (AMD3100) is a small-molecule CXCR4 antagonist that disrupts CXCL12/SDF-1 signaling, hematopoietic stem cell retention, and chemotaxis. Its strongest research uses are hematopoietic stem cell mobilization, cancer metastasis inhibition studies, and immune-cell trafficking assays, while disease-treatment conclusions require model-specific validation.
-
Salmonella Haem, SirM, and Phagocytosis Resistance
2026-08-31
The reference study identifies SirM as a Salmonella methyltransferase that increases HemL activity, elevates bacterial haem production, and suppresses macrophage phagocytosis through TLR4-dependent inhibition of Cdc42 activation. Its Tn-seq-to-animal-model workflow shows that haem biosynthesis can contribute to virulence through immune modulation, not only through iron acquisition.
-
Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor
2026-08-31
A high-throughput biochemical study identified merbromin as a selective inhibitor of SARS-CoV-2 3CLpro and characterized its mixed-type inhibition through kinetics, binding assays, and molecular docking. The work is important because it links screening activity with a preliminary selectivity profile while also defining the limitations of extrapolating enzyme inhibition to antiviral efficacy.
-
SGI-1027 and Everolimus in Renal Cancer
2026-08-30
A 2024 Advanced Science study identifies SGI-1027 as a methuosis inducer and shows that it cooperates with everolimus to suppress renal cancer through lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis. The findings suggest a way to diversify cell-death responses and address limitations associated with everolimus resistance, while highlighting the need for validation in broader and clinically relevant models.
-
Anlotinib Hydrochloride: From Mechanism to Translation
2026-08-29
An evidence-led perspective on how Anlotinib hydrochloride connects VEGFR2, PDGFRβ, and FGFR1 biology with reproducible angiogenesis assays, competitive positioning, and translational decision-making in cancer research.
-
Caspofungin: Reading Glucan-Targeted Assays
2026-08-28
Caspofungin is a lipopeptide antifungal drug whose value extends beyond growth inhibition. This article presents a mechanistic framework for connecting glucan synthase inhibition, resistance biology, and clinically relevant assay design in Candida research.
-
GW 4869: Exosome and Osteogenesis Workflows
2026-08-28
GW 4869 helps distinguish vesicle-mediated signaling from soluble-factor effects in stem-cell, bone-regeneration, inflammatory, and extracellular-vesicle studies. This practical guide connects neutral sphingomyelinase inhibition with lithium-engineered BMSC exosomes, assay controls, dosing logic, and troubleshooting.